Baxter's $298 Million Quarterly Profit Leans On A $253 Million Debt Gain, And An FDA Warning Letter Follows

Baxter retired $864 million of bonds for $600 million, while the FDA sent a Warning Letter over its Round Lake injectables plant.

Share
Baxter's $298 Million Quarterly Profit Leans On A $253 Million Debt Gain, And An FDA Warning Letter Follows

Baxter International's third-quarter profit from continuing operations swung to $298 million, and a $253 million pre-tax gain from buying back its own bonds below face value did much of the lifting, according to its 10-Q filed Thursday. The same filing carries a September FDA Warning Letter for its Round Lake, Illinois, sterile injectables plant, a regulatory episode the prior quarter's filing did not mention.

Bonds retired at a discount

Baxter, which makes sterile IV solutions, infusion systems, hospital beds, monitoring tools and other healthcare products, ran cash tender offers in August on four series of senior notes. It repaid $864 million of face value for a combined purchase price of $600 million, and booked the difference as the $253 million gain.

The gain sits inside other income of $253 million for the quarter, against $7 million a year earlier. Operating income was $225 million, up from $172 million. Income from continuing operations was $298 million, against a loss of $51 million in the third quarter of 2025, or $0.57 per diluted share.

Sales rose 5% to $2.98 billion. The company's adjusted earnings were $0.58 per share, down 16% on a higher tax rate, according to its earnings release, and it raised its full-year outlook for sales growth and adjusted earnings per share to $2.05 to $2.15, from $1.95 to $2.15.

Round Lake's Warning Letter

The FDA began inspecting Round Lake in March 2026 and issued a Form 483, a list of inspection observations, in April. The plant received an OAI classification, meaning official action indicated, in June, and the agency sent a Warning Letter in September.

The second-quarter 10-Q did not mention the episode. Baxter said it responded to the letter in October and is carrying out corrective actions. Separately, the filing says the company has stopped producing certain products at one of its specialty injectables plants, taking $39 million of restructuring charges.

Covenant room and lingering Novum hold

In August, Baxter amended its revolving credit agreement to raise the maximum net leverage ratio for five quarters, ending September 30, 2027. It had no borrowings under the $2.20 billion facility and could draw the full amount at quarter-end.

The Novum LVP infusion pump remains under a shipment and installation hold in the U.S. and Canada, and the filing says the timing of its release is uncertain. Securities class actions over Novum statements are pending.

Baxter declared a quarterly dividend of $0.01 per share, payable January 4, 2027, to holders of record November 27, 2026.

Baxter's raised leverage ceiling steps through September 30, 2027, while the Round Lake corrective work continues.

Sources

More on Baxter International

All Baxter International (BAX) coverage →